A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)
I-MAT
This trial is No longer recruiting
Registration number NCT04291885
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Mark Shackleton
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR